Straits Times Index
3,323.20 -6.89 (-0.21%) S&P 500
5,275.45 -30.59 (-0.58%) Dow
38,474.07 -378.79 (-0.97%) Nasdaq
16,966.08 -53.80 (-0.32%) Bitcoin USD
67,395.21 -276.70 (-0.41%) CMC Crypto 200
1,454.16 -30.53 (-2.06%)
OGN Dec 2024 17.500 call
| Previous close | 5.25 |
| Open | 5.25 |
| Bid | 4.10 |
| Ask | 4.40 |
| Strike | 17.50 |
| Expiry date | 2024-12-20 |
| Day's range | 5.25 - 5.25 |
| Contract range | N/A |
| Volume | |
| Open interest | 252 |
Business WireEuropean Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14
SHANGHAI, China & JERSEY CITY, N.J., May 24, 2024--European Medicines Agency validates Organon and Henlius marketing authorization filings for Prolia and Xgeva (denosumab) biosimilar candidate HLX14.
Business WireOrganon Announces Pricing of $1.0 Billion Senior Notes Offering
JERSEY CITY, N.J., May 08, 2024--Organon (NYSE: OGN) ("Organon"), a global healthcare company with a focus on women’s health, announced today that it, together with Organon Foreign Debt Co-Issuer B.V., a direct wholly-owned subsidiary of Organon, as co-issuer (the "Co-Issuer" and, together with Organon, the "Companies"), have priced an offering of $500 million of 6.750% senior secured notes due 2034 (the "Secured Notes") and $500 million of 7.875% senior unsecured notes due 2034 (the "Unsecured
Business WireOrganon Announces Proposed $1.0 Billion Senior Notes Offering
JERSEY CITY, N.J., May 07, 2024--Organon (NYSE: OGN) ("Organon"), a global healthcare company with a focus on women’s health, announced today that it, together with Organon Foreign Debt Co-Issuer B.V., a direct wholly-owned subsidiary of Organon, as co-issuer (the "Co-Issuer" and, together with Organon, the "Companies"), plan to offer, subject to market conditions, $500 million of senior secured notes due 2034 (the "secured notes") and $500 million of senior unsecured notes due 2034 (the "unsecu
